Hemab Therapeutics Holdings, Inc. share price logo

Hemab Therapeutics Holdings, Inc.

NASDAQ: COAG

Small Cap

$43.37

+2.19

(+5.32%)

Live

as on

Hemab Therapeutics Holdings, Inc. Stock Performance

as on November 4, 2026 at 4:58 am IST

  • Day's Low

    Day's High

    $41.15
    $44.28
    downward going graph

    5.12%

    Downside

    2.10%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Hemab Therapeutics Holdings, Inc. share price movements today

Previous Close
$41.18
Open
$42.30
Volume
199.8K
Market Cap
$1.9B
Day's Low - High
$41.15 - $44.28

Hemab Therapeutics Holdings, Inc. Historical Returns

1 Month Return
+ 32.37 %
3 Month Return
-8.49 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Hemab Therapeutics Holdings, Inc. Stock Fundamentals & Key Indicators

Check Hemab Therapeutics Holdings, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.9B

EPS (TTM)

-1.31

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-31.64

Industry PE ratio

-7.24

PEG Ratio

-0.32

EBITDA

-49.5M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-36.64%

Hemab Therapeutics Holdings, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Hemab Therapeutics Holdings, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$1.9BNA-31.640.00%0.00%
Neutral$88.5B-36.16%-27.78-12.57%0.00%
StrongBuy$141.7B192.56%32.2786.04%0.00%
Buy$95.5B47.41%19.7685.77%0.40%

Analyst Recommendation on Hemab Therapeutics Holdings, Inc. Stock

Based on 1 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'BUY' rating for Hemab Therapeutics Holdings, Inc.. Average target price of $64

Hemab Therapeutics Holdings, Inc. Share Price Target

Get share price movements and forecasts by analysts on Hemab Therapeutics Holdings, Inc..

Current Price

$43.37

Analyzed by

1 Analysts

High

$64

0

Low

$64

Hemab Therapeutics Holdings, Inc. target price $0, a slight upside of 0% compared to current price of $43.37. According to 1 analysts rating.

Indian Investors' Interest in Hemab Therapeutics Holdings, Inc. Stock

Search interest for Hemab Therapeutics Holdings, Inc. Stock has decreased by -32% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-32% versus previous 30 day period

Hemab Therapeutics Holdings, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2026
Jun 2026
Total Revenue
-
-
Gross Profit
-
0
Operating Income
-23
-26
EBITDA
-23
-26
Interest Expense
-
-
Depreciation
0
0
Income Before Tax
-22
-24
Income Tax Expense
0
0
Net Income
-22
-24
Net Profit Margin
0.00%
0.00%

Hemab Therapeutics Holdings, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2025
Total Revenue
-
Gross Profit
-
Operating Income
-70
EBITDA
-69
Interest Expense
-
Depreciation
0
Income Before Tax
-64
Income Tax Expense
0
Net Income
-63
Net Profit Margin
0.00%

Hemab Therapeutics Holdings, Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2026
Jun 2026
Net Income
-22
-24
Operating Cash Flow
-21
-22
Investing Cash Flow
-15
-107
Financing Cash Flow
0
317
Change in Cash
-38
187

Hemab Therapeutics Holdings, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2025
Net Income
-63
Operating Cash Flow
-61
Investing Cash Flow
-81
Financing Cash Flow
156
Change in Cash
13

Global Institutional Holdings in Hemab Therapeutics Holdings, Inc.

Check out the Institutions with significant holdings in Hemab Therapeutics Holdings, Inc..

Funds
Holdings
Ra Capital Management, Llc
16.72%
Peter Kolchinsky
16.72%
A S Novo
8.95%
SMALLCAP World Fund Inc
7.51%
Vanguard
1.91%

Hemab Therapeutics Holdings, Inc. News & Key Events

  • img

    Today's Timeline - 26 May

    Tue, 07:38 PM

    -

    Goldman Sachs initiates coverage of Hemab Therapeutics with a Buy rating and $36 price target, citing strong upside potential.

Insights on Hemab Therapeutics Holdings, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, COAG stock has moved up by 32.4%

About Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
OrganisationHemab Therapeutics Holdings, Inc.
Headquarters101 Main Street, Cambridge, MA, 02142, US
IndustryBiotechnology
CEOBenny Sorensen

Key Management of Hemab Therapeutics Holdings, Inc.

Name

Title

Dr. Catherine Eilleen Madigan M.D.

Chief Medical Officer

Dr. Ananthram Sreenivasa Murthy M.Sc., Ph.D.

Chief Operating Officer

Ms. Karen Weisbach

Chief People & Culture Officer

Ms. Cecile Bonvoisin M.Sc.

Senior Vice President of CMC & Manufacturing

Dr. Benny Sorensen M.D., Ph.D.

President, CEO & Director

Mr. Mads Nikolaj Behrndt-Eriksen M.Sc.

CFO & GM

FAQs

What is Hemab Therapeutics Holdings, Inc. share price today?

Hemab Therapeutics Holdings, Inc. share price today is $43.37 as on . Hemab Therapeutics Holdings, Inc. share today touched a day high of $44.28 and a low of $41.15.

What is the 52 week high and 52 week low for Hemab Therapeutics Holdings, Inc. share?

Hemab Therapeutics Holdings, Inc. share touched a 52 week high of $0.00 on and a 52 week low of $0.00 on . Hemab Therapeutics Holdings, Inc. stock price today i.e. is trending at $43.37,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Hemab Therapeutics Holdings, Inc.'s market capitalisation today?

Hemab Therapeutics Holdings, Inc. market capitalisation is $0.00T as on .

How to invest in Hemab Therapeutics Holdings, Inc. Stock (COAG) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Hemab Therapeutics Holdings, Inc. on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Hemab Therapeutics Holdings, Inc. Stock (COAG) from India?

Indian investors can start investing in Hemab Therapeutics Holdings, Inc. (COAG) shares with as little as ₹94.73999786376953 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹947.40 in Hemab Therapeutics Holdings, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Hemab Therapeutics Holdings, Inc. share’s latest price of $43.37 as on November 3, 2026 at 11:28 pm IST, you will get 0.2306 shares of Hemab Therapeutics Holdings, Inc.. Learn more about fractional shares .